AbbVie's Revenue
- AbbVie's annual revenue was $56.33 B in fiscal year 2024. The annual revenue increased $2.02 B from $54.32 B (in 2023) to $56.33 B (in 2024), representing a 3.71% year-over-year growth.
- AbbVie's quarterly revenue was $15.10 B in the quarter ending Dec 2024. The quarterly revenue increased $801.00 M from $14.30 B (in Q4: Sept 2023) to $15.10 B (in Q4: Sept 2024), representing a 5.60% year-over-year growth.
- The highest annual revenue for AbbVie was $58.05 B in fiscal year 2022.
- The lowest annual revenue was $22.86 B in fiscal year 2015.
- The average revenue was $41.34 B.
- Revenue is the amount of money generated by a business from sales of its goods or services. Refer to our glossary for more details, examples, and formulas.
Over the past 10 years (2015 - 2024):
Learn more about AbbVie's Revenue by Segment and Revenue by Region.
Check out competitors to AbbVie in a side-by-side comparison.
Explore additional financial metrics for AbbVie.
Definition of Revenue :
| 2014 | 19960000000.00 |
|---|---|
| 2015 | 22859000000.00 |
| 2016 | 25638000000.00 |
| 2017 | 28216000000.00 |
| 2018 | 32753000000.00 |
| 2019 | 33266000000.00 |
| 2020 | 45804000000.00 |
| 2021 | 56197000000.00 |
| 2022 | 58054000000.00 |
| 2023 | 54318000000.00 |
| 2024 | 56334000000.00 |
| Mar 2015 | 5040000000.00 |
|---|---|
| Jun 2015 | 5475000000.00 |
| Sep 2015 | 5944000000.00 |
| Dec 2015 | 6400000000.00 |
| Mar 2016 | 5958000000.00 |
| Jun 2016 | 6452000000.00 |
| Sep 2016 | 6432000000.00 |
| Dec 2016 | 6796000000.00 |
| Mar 2017 | 6538000000.00 |
| Jun 2017 | 6944000000.00 |
| Sep 2017 | 6995000000.00 |
| Dec 2017 | 7739000000.00 |
| Mar 2018 | 7934000000.00 |
| Jun 2018 | 8278000000.00 |
| Sep 2018 | 8236000000.00 |
| Dec 2018 | 8305000000.00 |
| Mar 2019 | 7828000000.00 |
| Jun 2019 | 8255000000.00 |
| Sep 2019 | 8479000000.00 |
| Dec 2019 | 8704000000.00 |
| Mar 2020 | 8619000000.00 |
| Jun 2020 | 10425000000.00 |
| Sep 2020 | 12902000000.00 |
| Dec 2020 | 13858000000.00 |
| Mar 2021 | 13010000000.00 |
| Jun 2021 | 13959000000.00 |
| Sep 2021 | 14342000000.00 |
| Dec 2021 | 14886000000.00 |
| Mar 2022 | 13538000000.00 |
| Jun 2022 | 14583000000.00 |
| Sep 2022 | 14812000000.00 |
| Dec 2022 | 15121000000.00 |
| Mar 2023 | 12225000000.00 |
| Jun 2023 | 13865000000.00 |
| Sep 2023 | 13927000000.00 |
| Dec 2023 | 14301000000.00 |
| Mar 2024 | 12310000000.00 |
| Jun 2024 | 14462000000.00 |
| Sep 2024 | 14460000000.00 |
| Dec 2024 | 15102000000.00 |
2024
AbbVie's annual revenue was $56.33 B in fiscal year 2024.
AbbVie's quarterly revenue was $12.31 B(Q1: Mar 2024), $14.46 B(Q2: Jun 2024), $14.46 B(Q3: Sep 2024), $15.10 B(Q4: Dec 2024) in fiscal year 2024.
2023
AbbVie's annual revenue was $54.32 B in fiscal year 2024.
AbbVie's quarterly revenue was $12.23 B(Q1: Mar 2023), $13.87 B(Q2: Jun 2023), $13.93 B(Q3: Sep 2023), $14.30 B(Q4: Dec 2023) in fiscal year 2023.
2022
AbbVie's annual revenue was $58.05 B in fiscal year 2024.
AbbVie's quarterly revenue was $13.54 B(Q1: Mar 2022), $14.58 B(Q2: Jun 2022), $14.81 B(Q3: Sep 2022), $15.12 B(Q4: Dec 2022) in fiscal year 2022.
2021
AbbVie's annual revenue was $56.20 B in fiscal year 2024.
AbbVie's quarterly revenue was $13.01 B(Q1: Mar 2021), $13.96 B(Q2: Jun 2021), $14.34 B(Q3: Sep 2021), $14.89 B(Q4: Dec 2021) in fiscal year 2021.
2020
AbbVie's annual revenue was $45.80 B in fiscal year 2024.
AbbVie's quarterly revenue was $8.62 B(Q1: Mar 2020), $10.43 B(Q2: Jun 2020), $12.90 B(Q3: Sep 2020), $13.86 B(Q4: Dec 2020) in fiscal year 2020.
2019
AbbVie's annual revenue was $33.27 B in fiscal year 2024.
AbbVie's quarterly revenue was $7.83 B(Q1: Mar 2019), $8.26 B(Q2: Jun 2019), $8.48 B(Q3: Sep 2019), $8.70 B(Q4: Dec 2019) in fiscal year 2019.
2018
AbbVie's annual revenue was $32.75 B in fiscal year 2024.
AbbVie's quarterly revenue was $7.93 B(Q1: Mar 2018), $8.28 B(Q2: Jun 2018), $8.24 B(Q3: Sep 2018), $8.31 B(Q4: Dec 2018) in fiscal year 2018.
2017
AbbVie's annual revenue was $28.22 B in fiscal year 2024.
AbbVie's quarterly revenue was $6.54 B(Q1: Mar 2017), $6.94 B(Q2: Jun 2017), $7.00 B(Q3: Sep 2017), $7.74 B(Q4: Dec 2017) in fiscal year 2017.
2016
AbbVie's annual revenue was $25.64 B in fiscal year 2024.
AbbVie's quarterly revenue was $5.96 B(Q1: Mar 2016), $6.45 B(Q2: Jun 2016), $6.43 B(Q3: Sep 2016), $6.80 B(Q4: Dec 2016) in fiscal year 2016.
2015
AbbVie's annual revenue was $22.86 B in fiscal year 2024.
AbbVie's quarterly revenue was $5.04 B(Q1: Mar 2015), $5.48 B(Q2: Jun 2015), $5.94 B(Q3: Sep 2015), $6.40 B(Q4: Dec 2015) in fiscal year 2015.
| 2014 | 0 |
|---|---|
| 2015 | +14.52 |
| 2016 | +12.16 |
| 2017 | +10.06 |
| 2018 | +16.08 |
| 2019 | +1.57 |
| 2020 | +37.69 |
| 2021 | +22.69 |
| 2022 | +3.30 |
| 2023 | -6.44 |
| 2024 | +3.71 |
| Q1: Mar 15 | 10.45 |
|---|---|
| Q2: Jun 15 | 11.14 |
| Q3: Sep 15 | 18.43 |
| Q4: Dec 15 | 17.39 |
| Q1: Mar 16 | 18.21 |
| Q2: Jun 16 | 17.84 |
| Q3: Sep 16 | 8.21 |
| Q4: Dec 16 | 6.19 |
| Q1: Mar 17 | 9.73 |
| Q2: Jun 17 | 7.63 |
| Q3: Sep 17 | 8.75 |
| Q4: Dec 17 | 13.88 |
| Q1: Mar 18 | 21.35 |
| Q2: Jun 18 | 19.21 |
| Q3: Sep 18 | 17.74 |
| Q4: Dec 18 | 7.31 |
| Q1: Mar 19 | -1.34 |
| Q2: Jun 19 | -0.28 |
| Q3: Sep 19 | 2.95 |
| Q4: Dec 19 | 4.80 |
| Q1: Mar 20 | 10.10 |
| Q2: Jun 20 | 26.29 |
| Q3: Sep 20 | 52.16 |
| Q4: Dec 20 | 59.21 |
| Q1: Mar 21 | 50.95 |
| Q2: Jun 21 | 33.90 |
| Q3: Sep 21 | 11.16 |
| Q4: Dec 21 | 7.42 |
| Q1: Mar 22 | 4.06 |
| Q2: Jun 22 | 4.47 |
| Q3: Sep 22 | 3.28 |
| Q4: Dec 22 | 1.58 |
| Q1: Mar 23 | -9.70 |
| Q2: Jun 23 | -4.92 |
| Q3: Sep 23 | -5.97 |
| Q4: Dec 23 | -5.42 |
| Q1: Mar 24 | 0.70 |
| Q2: Jun 24 | 4.31 |
| Q3: Sep 24 | 3.83 |
| Q4: Dec 24 | 5.60 |
2024
AbbVie’s annual revenue increased +3.71% during fiscal year 2024 compared to 2023. It represents a growth of $2.02 B from $54.32 B (in 2023) to $56.33 B (in 2024).
2023
AbbVie’s annual revenue decreased -6.44% during fiscal year 2023 compared to 2022. It represents a decline of -$3.74 B from $58.05 B (in 2022) to $54.32 B (in 2023).
2022
AbbVie’s annual revenue increased +3.30% during fiscal year 2022 compared to 2021. It represents a growth of $1.86 B from $56.20 B (in 2021) to $58.05 B (in 2022).
2021
AbbVie’s annual revenue increased +22.69% during fiscal year 2021 compared to 2020. It represents a growth of $10.39 B from $45.80 B (in 2020) to $56.20 B (in 2021).
2020
AbbVie’s annual revenue increased +37.69% during fiscal year 2020 compared to 2019. It represents a growth of $12.54 B from $33.27 B (in 2019) to $45.80 B (in 2020).
2019
AbbVie’s annual revenue increased +1.57% during fiscal year 2019 compared to 2018. It represents a growth of $513.00 M from $32.75 B (in 2018) to $33.27 B (in 2019).
2018
AbbVie’s annual revenue increased +16.08% during fiscal year 2018 compared to 2017. It represents a growth of $4.54 B from $28.22 B (in 2017) to $32.75 B (in 2018).
2017
AbbVie’s annual revenue increased +10.06% during fiscal year 2017 compared to 2016. It represents a growth of $2.58 B from $25.64 B (in 2016) to $28.22 B (in 2017).
2016
AbbVie’s annual revenue increased +12.16% during fiscal year 2016 compared to 2015. It represents a growth of $2.78 B from $22.86 B (in 2015) to $25.64 B (in 2016).
2015
AbbVie’s annual revenue increased +14.52% during fiscal year 2015 compared to 2014. It represents a growth of $2.90 B from $19.96 B (in 2014) to $22.86 B (in 2015).
Summary Table (Annual)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| 2024 | $56.33 B | +3.71% |
| 2023 | $54.32 B | -6.44% |
| 2022 | $58.05 B | +3.30% |
| 2021 | $56.20 B | +22.69% |
| 2020 | $45.80 B | +37.69% |
| 2019 | $33.27 B | +1.57% |
| 2018 | $32.75 B | +16.08% |
| 2017 | $28.22 B | +10.06% |
| 2016 | $25.64 B | +12.16% |
| 2015 | $22.86 B | +14.52% |
Summary Table (Quarterly)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| Q4: Dec 24 | $15.10 B | 5.60% |
| Q3: Sep 24 | $14.46 B | 3.83% |
| Q2: Jun 24 | $14.46 B | 4.31% |
| Q1: Mar 24 | $12.31 B | 0.70% |
| Q4: Dec 23 | $14.30 B | -5.42% |
| Q3: Sep 23 | $13.93 B | -5.97% |
| Q2: Jun 23 | $13.87 B | -4.92% |
| Q1: Mar 23 | $12.23 B | -9.70% |
| Q4: Dec 22 | $15.12 B | 1.58% |
| Q3: Sep 22 | $14.81 B | 3.28% |
| Q2: Jun 22 | $14.58 B | 4.47% |
| Q1: Mar 22 | $13.54 B | 4.06% |
| Q4: Dec 21 | $14.89 B | 7.42% |
| Q3: Sep 21 | $14.34 B | 11.16% |
| Q2: Jun 21 | $13.96 B | 33.90% |
| Q1: Mar 21 | $13.01 B | 50.95% |
| Q4: Dec 20 | $13.86 B | 59.21% |
| Q3: Sep 20 | $12.90 B | 52.16% |
| Q2: Jun 20 | $10.43 B | 26.29% |
| Q1: Mar 20 | $8.62 B | 10.10% |
| Q4: Dec 19 | $8.70 B | 4.80% |
| Q3: Sep 19 | $8.48 B | 2.95% |
| Q2: Jun 19 | $8.26 B | -0.28% |
| Q1: Mar 19 | $7.83 B | -1.34% |
| Q4: Dec 18 | $8.31 B | 7.31% |
| Q3: Sep 18 | $8.24 B | 17.74% |
| Q2: Jun 18 | $8.28 B | 19.21% |
| Q1: Mar 18 | $7.93 B | 21.35% |
| Q4: Dec 17 | $7.74 B | 13.88% |
| Q3: Sep 17 | $7.00 B | 8.75% |
| Q2: Jun 17 | $6.94 B | 7.63% |
| Q1: Mar 17 | $6.54 B | 9.73% |
| Q4: Dec 16 | $6.80 B | 6.19% |
| Q3: Sep 16 | $6.43 B | 8.21% |
| Q2: Jun 16 | $6.45 B | 17.84% |
| Q1: Mar 16 | $5.96 B | 18.21% |
| Q4: Dec 15 | $6.40 B | 17.39% |
| Q3: Sep 15 | $5.94 B | 18.43% |
| Q2: Jun 15 | $5.48 B | 11.14% |
| Q1: Mar 15 | $5.04 B | 10.45% |
